<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04998214</url>
  </required_header>
  <id_info>
    <org_study_id>liver in COVID-19</org_study_id>
    <nct_id>NCT04998214</nct_id>
  </id_info>
  <brief_title>Hepatic Manifestations and Effect of Long COVID-19 on Patients With Chronic Liver Disease</brief_title>
  <official_title>Hepatic Manifestations and Effect of Long COVID-19 on Patients With Chronic Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To measure the frequency of persistent liver dysfunction (raised liver enzymes, serum&#xD;
      albumin, prothrombin time, etc) in recovered COVID -19 patients.&#xD;
&#xD;
      To compare the hepatic manifestations in post COVID -19 patients with and without liver&#xD;
      disease&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The digestive tract, particularly the liver, has recently been reported to be affected by&#xD;
      SARS-CoV-2. Although abnormal liver enzymes were regularly described as an extra-pulmonary&#xD;
      clinical feature, and almost one half of patients experienced grades of hepatic injury. liver&#xD;
      damage in patients with SARS infections was primarily manifested in the mild and moderate&#xD;
      elevation of alanine and/or aspartate aminotransferases (ALT and AST) with some degree of&#xD;
      hypoalbuminemia and hyperbilirubinemia during the early stage of the illness.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 19, 2021</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>to evaluate the long term effect of COVID 19 on the liver</measure>
    <time_frame>1 month</time_frame>
    <description>to evaluate the changes in liver function (bilirubin ,liver enzymes , albumin , prothrombin time and INR in patients post COVID_19</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>: Effect of COVID 19 on diseased liver</measure>
    <time_frame>1 month</time_frame>
    <description>to evaluate the changes in liver function(bilirubin , liver enzymes , albumin , prothrombin time , INR) in cirrhotic post COVID_19</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">65</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>control group non cirrhotic</arm_group_label>
    <description>compare liver function 1m after COVID-19 and that at beginning of infection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cirrhotic patients</arm_group_label>
    <description>compare liver function 1m after COVID-19 and that at beginning of infection</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>liver function , prothrombin time , INR , US .</intervention_name>
    <description>analytic</description>
    <arm_group_label>cirrhotic patients</arm_group_label>
    <arm_group_label>control group non cirrhotic</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients older than 18 years old, 1 month post COVID 19 infection.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients previously diagnosed by COVID 19 eg : PCR and / or HRCT chest, lab of more&#xD;
             than 1 month duration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients less than 18 y.&#xD;
&#xD;
          -  Patients with acute COVID 19.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Huda Mokhtar</last_name>
    <phone>01026865760</phone>
    <email>hudamokhtar2571994@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Khaled Abu Bakr</last_name>
    <phone>01005016122</phone>
  </overall_contact_backup>
  <reference>
    <citation>Ye ZW, Yuan S, Yuen KS, Fung SY, Chan CP, Jin DY. Zoonotic origins of human coronaviruses. Int J Biol Sci. 2020 Mar 15;16(10):1686-1697. doi: 10.7150/ijbs.45472. eCollection 2020. Review.</citation>
    <PMID>32226286</PMID>
  </reference>
  <reference>
    <citation>Fung SY, Yuen KS, Ye ZW, Chan CP, Jin DY. A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: lessons from other pathogenic viruses. Emerg Microbes Infect. 2020 Mar 14;9(1):558-570. doi: 10.1080/22221751.2020.1736644. eCollection 2020. Review.</citation>
    <PMID>32172672</PMID>
  </reference>
  <reference>
    <citation>Sultan S, Lim JK, Altayar O, Davitkov P, Feuerstein JD, Siddique SM, Falck-Ytter Y, El-Serag HB; AGA Institute. Electronic address: ewilson@gastro.org. AGA Rapid Recommendations for Gastrointestinal Procedures During the COVID-19 Pandemic. Gastroenterology. 2020 Aug;159(2):739-758.e4. doi: 10.1053/j.gastro.2020.03.072. Epub 2020 Apr 1. Review.</citation>
    <PMID>32247018</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 19, 2021</study_first_submitted>
  <study_first_submitted_qc>August 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2021</study_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Huda Mokhtar Salim</investigator_full_name>
    <investigator_title>clinical professor : Mohammed El _Taher Abdel_Rahman .</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

